Literature DB >> 3829284

Haemodynamic effects of clonidine injected epidurally in halothane-anaesthetized dogs.

M Ghignone, O Calvillo, L Quintin, S Caple, R Kozody.   

Abstract

The haemodynamic effects of clonidine administered in the epidural space were studied in 16 halothane-anaesthetized dogs. The animals were randomly assigned to two groups: Group I received three doses of 3 ml of normal saline, Group II received three doses of 3 micrograms X kg-1 of clonidine, through an epidural catheter, whose tip was located between L2-T11. Control haemodynamic measurements were taken one hour after completion of the surgical preparation (period P1); they were repeated every 45 minutes after each incremental dose (periods P2, P3, P4) and 105 minutes after a total cumulative dose of 9 micrograms X kg-1 of clonidine or 9 ml of saline were given (period P5). No significant changes over time were observed in Group I. In Group II clonidine produced statistically significant reductions of systemic blood pressure (BP), mean left ventricular pressure (LV), heart rate (HR), cardiac output (CO) and peak LV dP/dt only after a total clonidine dose of 9 micrograms X kg-1 and these changes were sustained. BP fell 15 per cent, CO 21 per cent, HR 25 per cent, LV 20 per cent and peak LV dP/dt 30 per cent when P5 measurements were compared to control values within Group II (p less than 0.05). These haemodynamic effects of clonidine are likely due to minimal systemic absorption and/or cephalad spread of the drug towards its site of action in the brain stem. The reductions of HR, CO, BP, and isovolemic indices of contractility are likely explained by a reduction of sympathetic outflow at the spinal cord and medulla oblongata levels as well as increased parasympathetic tone.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3829284     DOI: 10.1007/BF03007681

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  27 in total

1.  Hemodynamic determinants of the maximal rate of rise of left ventricular pressure.

Authors:  A G WALLACE; N S SKINNER; J H MITCHELL
Journal:  Am J Physiol       Date:  1963-07

2.  Effect of the hypotensive drug ST 155 (Catapres) on the heart and peripheral circulation.

Authors:  W G Nayler; J M Price; J B Swann; I McInnes; D Race; T E Lowe
Journal:  J Pharmacol Exp Ther       Date:  1968-11       Impact factor: 4.030

Review 3.  Pharmacology of clonidine.

Authors:  W A Pettinger
Journal:  J Cardiovasc Pharmacol       Date:  1980       Impact factor: 3.105

4.  Intrathecal morphine tolerance: use of intrathecal clonidine, DADLE, and intraventricular morphine.

Authors:  D W Coombs; R L Saunders; D Lachance; S Savage; T S Ragnarsson; L E Jensen
Journal:  Anesthesiology       Date:  1985-03       Impact factor: 7.892

5.  Inhibition of sympathetic preganglionic neurons by catecholamines and clonidine: mediation by an alpha-adrenergic receptor.

Authors:  P G Guyenet; J B Cabot
Journal:  J Neurosci       Date:  1981-08       Impact factor: 6.167

6.  Spinal noradrenergic terminal system mediates antinociception.

Authors:  S V Reddy; T L Yaksh
Journal:  Brain Res       Date:  1980-05-12       Impact factor: 3.252

7.  Halothane depresses baroreflex control of heart rate in man.

Authors:  P C Duke; D Fownes; J G Wade
Journal:  Anesthesiology       Date:  1977-03       Impact factor: 7.892

8.  Dose-dependent suppression of norepinephrine appearance rate in plasma by clonidine in man.

Authors:  R C Veith; J D Best; J B Halter
Journal:  J Clin Endocrinol Metab       Date:  1984-07       Impact factor: 5.958

9.  Effects of clonidine on canine cardiac neuroeffector structures controlling heart rate.

Authors:  I Cavero; A G Roach
Journal:  Br J Pharmacol       Date:  1980-10       Impact factor: 8.739

10.  Presynaptic effect of clonidine on unmyelinated afferent fibers in the spinal cord of the cat.

Authors:  O Calvillo; M Ghignone
Journal:  Neurosci Lett       Date:  1986-03-14       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.